DermTech, Inc. (DMTKQ)

Market Cap	35.00
Revenue (ttm)	15.66M
Net Income (ttm)	-89.63M
Shares Out	35.26M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	1,569
Open	0.0001
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	1.90
RSI	45.37
Earnings Date	Feb 28, 2025

About DermTech

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• CEO: Bret Christensen
• Employees: 208
• Stock Exchange: OTCMKTS
• Ticker Symbol: DMTKQ

Financial Performance

In 2023, DermTech's revenue was $15.30 million, an increase of 5.36% compared to the previous year's $14.52 million. Losses were -$100.89 million, -13.54% less than in 2022.